Christmas 2020 roundup from the TherapeutAix team
As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12…
Challenges in inhaled drug therapy
In the first blog of this series1, we highlighted that, despite the potential advantages, there appear to be only a…
Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib,…
Targeted Delivery in IPF: Inhalation Therapy
As part of a three-part series, we are looking at targeted delivery in idiopathic pulmonary fibrosis (IPF). This week, we…
Alderley Analytical and Peak Proteins join the TherapeutAix Network
Following a recent collaboration, TherapeutAix is delighted to announce the addition of Alderley Analytical and Peak Proteins as network partners.…
